Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan
Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan
复制标题
肿瘤位置与野生型 Ras 结直肠癌患者中 Braf 和 Pik3ca 突变的患病率相关：日本的一项前瞻性多中心队列研究
DOI：
10.1016/j.tranon.2020.100786
复制
发表时间：
2020
影响因子：
5
通讯作者：
Y Yatabe and Y Tsutsumi
中科院分区：
文献类型：
--
作者：
Tachibana M;M Saito;J Kobayashi;T Isono;Y Yatabe and Y Tsutsumi
背景技术背景：原发肿瘤位置是一个关键的预后因素，也影响抗表皮生长因子受体（EGFR）治疗野生型RAS（KRAS/NRAS）转移性结直肠癌（CRC）的疗效。然而，BRAF和磷脂酰肌醇-4，5-二磷酸3-激酶催化亚基α（PIK 3CA）突变的发生率和原发肿瘤location.METHODS之间的关联尚不清楚：我们前瞻性地收集了2014年8月至2016年4月期间来自15家医院的患者的肿瘤样本和临床数据，使用聚合酶链反应为基础的测定来调查RAS，BRAF和PIK 3CA突变。根据原发肿瘤的位置，患者被分类为右侧（从盲肠到脾曲）和左侧结果：共调查577例结直肠癌患者，其中RAS野生型331例（57%）;在这331名患者中，分别有10.5%、4.8%和5.9%的患者携带BRAFV 600 E、BRAFnon-V600 E和PIK 3CA突变。BRAF/PIK 3CA突变在女性、右侧肿瘤患者且患者合并腹膜转移病例较少见，肝转移患者较少见。右侧肿瘤患者BRAFV 600 E和PIK 3CA突变的患病率高于左侧肿瘤患者（分别为32.3%和4.8%以及17.2%和3.6%）。超过一半的右侧CRC和野生型RA患者携带BRAF/PIK 3CA突变，包括BRAF非V600 E，这可能导致右侧和左侧CRC之间抗EGFR功效的差异。
BACKGROUND: Primary tumor location is a critical prognostic factor that also impacts the efficacy of anti-epidermal growth factor receptor (EGFR) therapy in wild-typeRAS(KRAS/NRAS) metastatic colorectal cancer (CRC). However, the association between the incidence ofBRAFand phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations and primary tumor location remains unclear.METHODS: We prospectively collected tumor samples and clinical data of patients from 15 hospitals between August 2014 and April 2016 to investigateRAS,BRAF, andPIK3CAmutations using a polymerase chain reaction-based assay. According to the primary tumor location, patients were classified to right-sided (from cecum to splenic flexure) and left-sided (from descending colon to rectum) tumor groups.RESULTS: In total, 577 patients with CRC were investigated, 331 patients (57%) had CRC with wild-typeRAS; of these 331 patients, 10.5%, 4.8%, and 5.9% patients harboredBRAFV600E,BRAFnon-V600E, andPIK3CAmutations, respectively.BRAF/PIK3CAmutations were more frequent in females, patients with right-sided tumors, and patients with peritoneal metastasis cases and less frequent in patients with liver metastases. The prevalence rates ofBRAFV600EandPIK3CAmutations were higher in patients with right-sided tumors than in those with left-sided tumors (32.3% vs. 4.8% and 17.2% vs. 3.6%, respectively).CONCLUSIONS: More than half of the patients with right-sided CRC and wild-typeRASharboredBRAF/PIK3CAmutations, includingBRAFnon-V600E, which may contribute to the difference in the anti-EGFR efficacy between the right- and left-sided CRC.
使用 Luminex xMAP 技术对新开发的多重试剂盒进行临床验证，用于同时检测结直肠癌中的 RAS 和 BRAF 突变：RASKET-B 研究的结果1
影响因子：
4.8
作者：
H. Taniguchi;W. Okamoto;K. Muro;K. Akagi;H. Hara;T. Nishina;T. Kajiwara;T. Denda;S. Hironaka;T. Kudo;T. Satoh;T. Yamanaka;Y. Abe;Yoshiyuki Fukushima;T. Yoshino
通讯作者：
T. Yoshino
针对结直肠癌所有 RAS 突变的新型多重试剂盒的临床验证：RASKET（RAS 关键测试）前瞻性多中心结果……
DOI：
--
发表时间：
2014
期刊：
影响因子：
--
作者：
Kudo T.;Hironaka S;Okamoto W;Yoshino T;Muro K;Taniguchi H;Akagi K;Nishina T;Kajiwara T;DendaT.
通讯作者：
DendaT.